Recodgen Frequently Asked Questions (FAQ)
What is Recodgen's latest funding round?
Recodgen's latest funding round is Other Investors.
Who are the investors of Recodgen?
Investors of Recodgen include ARCH Venture Partners.
Who are Recodgen's competitors?
Competitors of Recodgen include CoImmune, Selexys Pharmaceuticals, Sorbent Therapeutics, Altheus Therapeutics, Marval Biosciences and 10 more.
Compare Recodgen to Competitors
Which is using a platform-technology approach to develop antibody and peptide-based therapeutics against select targets.
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.
NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.
Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.